<!DOCTYPE html>
<html>
<head>
    <title>全文阅读--XML全文阅读--中国知网</title>
    <link rel="icon" href="/kxreader/favicon.ico" />
    <link rel="shortcut Icon" href="/kxreader/favicon.ico" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
    <meta name="keywords" content="文献 XML KBASE CNKI 中国知网" />
    <meta name="description" content="XML文献检索" />
    <link href="/kxreader/Content/css/detail?v=NOOK-mvTMnxl11s6oPYV0boPXN3iP4N7Rc-A56nk4KI1" rel="stylesheet"/>

    <script type="text/javascript">
        var APPPATH = '/kxreader';
    </script>
</head>

<body>
    
<script type="text/javascript" src="//login.cnki.net/TopLogin/api/loginapi/get?type=top&amp;localCSS=&amp;returnurl=%2f%2fkns.cnki.net%2fKXReader%2fDetail%3fTIMESTAMP%3d637141665820576250%26DBCODE%3dCJFD%26TABLEName%3dCJFDLAST2019%26FileName%3dXXGK201904031%26RESULT%3d1%26SIGN%3dli3Zk0pQmz0IDxLOktC1KTXPv0c%253d"></script>

<div id="headerBox" class="header">
    <div class="topbar">
        <div class="textalign">
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201904031&amp;align=md">
                <i class="icon-cen active" title="居中对齐"></i>
            </a>
            <a href="/kxreader/Detail?dbcode=CJFD&amp;filename=XXGK201904031&amp;align=lt">
                <i class="icon-left " title="左对齐"></i>
            </a>
        </div>
        <h6 class="free-tip"><i class="icon"></i>HTML阅读开放试用阶段，欢迎体验！</h6>
    </div>
</div>

    



<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201904031&amp;v=MjIxMDdUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblZMek1QVFhNWmJHNEg5ak1xNDlHWllRS0RIODR2UjQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>

    <div class="main">

        

    <div class="sidebar-a">
        <!--sidebar start-->
        <div class="sidenav">
            <div class="arrow"><span></span></div>
            <!--sidebar_list start-->
            <dl class="sidenav-list">
                    <dt class="tit">目录结构</dt>
                            <dd class="guide">
                                    <p><a href="#55" data-title="&lt;b&gt;1&lt;/b&gt; COPD&lt;b&gt;基础疾病的治疗&lt;/b&gt; "><b>1</b> COPD<b>基础疾病的治疗</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#57" data-title="&lt;b&gt;2 非药物治疗&lt;/b&gt; "><b>2 非药物治疗</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#58" data-title="2.1 戒烟">2.1 戒烟</a></li>
                                                <li><a href="#60" data-title="2.2 长期氧疗 (long-term oxygen therapy, LTOT) ">2.2 长期氧疗 (long-term oxygen therapy, LTOT) </a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#63" data-title="&lt;b&gt;3&lt;/b&gt; PAH&lt;b&gt;的药物治疗&lt;/b&gt; "><b>3</b> PAH<b>的药物治疗</b></a><i></i></p>
                                                                    <ul class="contentbox">
                                                <li><a href="#64" data-title="3.1 传统药物">3.1 传统药物</a></li>
                                                <li><a href="#70" data-title="3.2 针对内皮细胞功能紊乱的靶向药物">3.2 针对内皮细胞功能紊乱的靶向药物</a></li>
                                                <li><a href="#78" data-title="3.3 其他新型靶向药物">3.3 其他新型靶向药物</a></li>
                                    </ul>
                            </dd>
                            <dd class="guide">
                                    <p><a href="#80" data-title="&lt;b&gt;4 中药治疗&lt;/b&gt; "><b>4 中药治疗</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#82" data-title="&lt;b&gt;5 手术治疗&lt;/b&gt; "><b>5 手术治疗</b></a><i></i></p>
                                                            </dd>
                            <dd class="guide">
                                    <p><a href="#84" data-title="&lt;b&gt;6 结 语&lt;/b&gt; "><b>6 结 语</b></a><i></i></p>
                                                            </dd>
                                    <dd class="guide">
                                        <h6>
                                            <p><a href="#a_bibliography">参考文献</a> </p>
                                        </h6>
                                    </dd>

            </dl>
        </div>
        <!--sidebar end-->
        &nbsp;
        <!--此处有一空格符 勿删-->
    </div>

                <div class="sidebar-b three-collumn" style="width:0;">
            <div class="refer" style="width: 0;">
                <div class="arrow off" title="参考文献"><span></span></div>
                <div class="js-scrollbox" >
                    
                    <div class="subbox active">
                        <h4>
                            <span class="tit">参考文献</span>
                            <a class="close" href="javascript:void(0)">x</a>
                        </h4>
                        <div class="side-scroller">
                            <ul class="refer-list">
                                <li id="110">


                                    <a id="bibliography_1" title="Viegi G, Scognamiglio A, Baldacci S, et al.Epidemiology of chronic obstructive pulmonary disease (COPD) [J].Respiration, 2001, 68 (1) :4-19." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Epidemiology of chronic obstructive pulmonary disease (COPD)">
                                        <b>[1]</b>
                                        Viegi G, Scognamiglio A, Baldacci S, et al.Epidemiology of chronic obstructive pulmonary disease (COPD) [J].Respiration, 2001, 68 (1) :4-19.
                                    </a>
                                </li>
                                <li id="112">


                                    <a id="bibliography_2" title="Gali&#232;N, Humbert M, Vachiery JL, et al.2015 ESC/ERSGuidelines for the Diagnosis and Treatment of Pulmonary Hypertension:The joint task force for the diagnosis and treatment of pulmonary Hypertens of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) :Endorsed by:Association for European Paediatric and Congenital cardiology (AEPC) , international Society for Heart and Lung Transplantation (ISHLT) [J].Eur Heart J, 2016, 37 (1) :67-119." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=2015 ESC/ERSGuidelines for the Diagnosis and Treatment of Pulmonary Hypertension:The joint task force for the diagnosis and treatment of pulmonary Hypertens of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS):Endorsed by:As">
                                        <b>[2]</b>
                                        Gali&#232;N, Humbert M, Vachiery JL, et al.2015 ESC/ERSGuidelines for the Diagnosis and Treatment of Pulmonary Hypertension:The joint task force for the diagnosis and treatment of pulmonary Hypertens of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) :Endorsed by:Association for European Paediatric and Congenital cardiology (AEPC) , international Society for Heart and Lung Transplantation (ISHLT) [J].Eur Heart J, 2016, 37 (1) :67-119.
                                    </a>
                                </li>
                                <li id="114">


                                    <a id="bibliography_3" title="Lee JH, Oh YM, Seo JB, et al.Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxiema[J].Int J Tubere Lung Dis, 2011, 15 (6) :830-837." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxaemia">
                                        <b>[3]</b>
                                        Lee JH, Oh YM, Seo JB, et al.Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxiema[J].Int J Tubere Lung Dis, 2011, 15 (6) :830-837.
                                    </a>
                                </li>
                                <li id="116">


                                    <a id="bibliography_4" title="Zielin&#39;ski J, Tobiasz M, Hawrylkiewicz I, et al.Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients:a 6-year prospective study[J].Chest, 1998, 113 (1) :65-70." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES5BE5F65D13A2B90743D2A064E598942C&amp;v=MTk4OTJEZzR3enhFWDZVdC9PWC9rcUdjd2NMcWRRYmpzQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeExxNHc2dz1OaWZPZmJiS2E5UzZxWW94WmVoKw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[4]</b>
                                        Zielin&#39;ski J, Tobiasz M, Hawrylkiewicz I, et al.Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients:a 6-year prospective study[J].Chest, 1998, 113 (1) :65-70.
                                    </a>
                                </li>
                                <li id="118">


                                    <a id="bibliography_5" title="Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:a clinical trial.Nocturnal Oxygen Therapy Trial Group[J].Ann Intern Med, 1980, 93 (3) :391-398." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial">
                                        <b>[5]</b>
                                        Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:a clinical trial.Nocturnal Oxygen Therapy Trial Group[J].Ann Intern Med, 1980, 93 (3) :391-398.
                                    </a>
                                </li>
                                <li id="120">


                                    <a id="bibliography_6" title="Halcox JP, Deanfield JE.Beyond the laboratory:clinical implications for statin pleiotropy[J].Circulation, 2004, 109 (21Suppl 1) :II42-II48." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000030749&amp;v=MTUzMzZyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRndUYVJZPU5pZmNaYks2SDlIUHI0OUZaT2dQQzNnd29CTVQ2VDRQUUgvaQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[6]</b>
                                        Halcox JP, Deanfield JE.Beyond the laboratory:clinical implications for statin pleiotropy[J].Circulation, 2004, 109 (21Suppl 1) :II42-II48.
                                    </a>
                                </li>
                                <li id="122">


                                    <a id="bibliography_7" title="马航, 何海艳, 邱海艳, 等.阿托伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者的临床作用及其机制[J].山西医科大学大学学报, 2014, 45 (3) :204-208." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SXYX201403014&amp;v=MTU3NDg2ajU0TzN6cXFCdEdGckNVUjdxZlp1Wm1GeWpuVkx6TU5qWFNkckc0SDlYTXJJOUVZSVFLREg4NHZSNFQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[7]</b>
                                        马航, 何海艳, 邱海艳, 等.阿托伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者的临床作用及其机制[J].山西医科大学大学学报, 2014, 45 (3) :204-208.
                                    </a>
                                </li>
                                <li id="124">


                                    <a id="bibliography_8" title="孙娟, 丁毅鹏.辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J].海南医学, 2014, 25 (2) :164-166." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=HAIN201402004&amp;v=MTQ2NDhIOVhNclk5RllJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnVabUZ5am5WTHpNTFN6Q1lMRzQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[8]</b>
                                        孙娟, 丁毅鹏.辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J].海南医学, 2014, 25 (2) :164-166.
                                    </a>
                                </li>
                                <li id="126">


                                    <a id="bibliography_9" title="Rubin LJ, Badesch DB, Barst RJ, et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med, 2002, 346 (12) :896-903." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Bosentan therapy for pulmonary arterial hypertension">
                                        <b>[9]</b>
                                        Rubin LJ, Badesch DB, Barst RJ, et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med, 2002, 346 (12) :896-903.
                                    </a>
                                </li>
                                <li id="128">


                                    <a id="bibliography_10" title="Simonneau G, Galie N, Jansa P, et al.Long-term Results:from the EARLY study of bosentan in WHO functional class IIpulmonary arterial hypertension patients[J].Int J Cardiol, 2014, 172 (2) :332-339." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14032300042824&amp;v=MjE3NDRGaW5sVXJmSUlGd1RhUlk9TmlmT2ZiSzhIdExPckk5RlpPOE5CSDQ5b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[10]</b>
                                        Simonneau G, Galie N, Jansa P, et al.Long-term Results:from the EARLY study of bosentan in WHO functional class IIpulmonary arterial hypertension patients[J].Int J Cardiol, 2014, 172 (2) :332-339.
                                    </a>
                                </li>
                                <li id="130">


                                    <a id="bibliography_11" title="Gali&#232;N, Olschewski H, Oudiz RJ, et al.Ambrisentan for the treatment of pulmonary arterial hypertension:results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (AR-IES) study 1and 2[J].Circulation, 2008, 117 (23) :3010-3019." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000036164&amp;v=MjU1OTY2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGd1RhUlk9TmlmY1piSzZIOUhQcjQ5RlpPZ0pEWG85b0JNVA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[11]</b>
                                        Gali&#232;N, Olschewski H, Oudiz RJ, et al.Ambrisentan for the treatment of pulmonary arterial hypertension:results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (AR-IES) study 1and 2[J].Circulation, 2008, 117 (23) :3010-3019.
                                    </a>
                                </li>
                                <li id="132">


                                    <a id="bibliography_12" title="Pulido T, Adzerikho I, Channick RN, et al.Macitentan and morbidity and mortality in pulmonary arterial hypertension[J].N Engl J Med, 2013, 369 (9) :809-818." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Macitentan and morbidity and mortality in pulmonary arterial hypertension">
                                        <b>[12]</b>
                                        Pulido T, Adzerikho I, Channick RN, et al.Macitentan and morbidity and mortality in pulmonary arterial hypertension[J].N Engl J Med, 2013, 369 (9) :809-818.
                                    </a>
                                </li>
                                <li id="134">


                                    <a id="bibliography_13" title="Channick RN, Delcroix M, Ghofrani HA, et al.Effect of macitentan on hospitalizations:results:from the SERAPHINtrial[J].JACC Heart Fail, 2015, 3 (1) :1-8." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14110700520358&amp;v=MDkyNjBxSTlGWWVrUEQza3hvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRndUYVJZPU5pZk9mYks4SDlETQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[13]</b>
                                        Channick RN, Delcroix M, Ghofrani HA, et al.Effect of macitentan on hospitalizations:results:from the SERAPHINtrial[J].JACC Heart Fail, 2015, 3 (1) :1-8.
                                    </a>
                                </li>
                                <li id="136">


                                    <a id="bibliography_14" title="张晓春, 管丽华, 潘文志, 等.肺动脉高压靶向药物治疗进展[J].上海医药, 2014, 35 (15) :9-13." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SYIY201415006&amp;v=MDgxNDZxZlp1Wm1GeWpuVkx6TU5qVENkN0c0SDlYTnFvOUZZb1FLREg4NHZSNFQ2ajU0TzN6cXFCdEdGckNVUjc=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[14]</b>
                                        张晓春, 管丽华, 潘文志, 等.肺动脉高压靶向药物治疗进展[J].上海医药, 2014, 35 (15) :9-13.
                                    </a>
                                </li>
                                <li id="138">


                                    <a id="bibliography_15" title="Tokunaga N, Ogawa A, Ito H, et al.Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial Hypertens[J].J Cardiol, 2016, 68 (6) :542-547." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES9AED8CCF91CB6B02393081EA42AAEDBD&amp;v=MTExODFPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhMcTR3Nnc9TmlmT2ZickphNlhFM1B3emJlcDhmbnBMenhRUTR6eDlRSDZYM1JZM0NNUGhNY2pyQw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[15]</b>
                                        Tokunaga N, Ogawa A, Ito H, et al.Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial Hypertens[J].J Cardiol, 2016, 68 (6) :542-547.
                                    </a>
                                </li>
                                <li id="140">


                                    <a id="bibliography_16" title="Jing ZC, Parikh K, Pulido T, et al.Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension:a randomized, controlled trial[J].Circulation, 2013, 127 (5) :624-633." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK13030500001084&amp;v=MTI2NDNUYVJZPU5pZmNaYks3SHRMTXFvOUZaT3NPREhROW9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGdw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[16]</b>
                                        Jing ZC, Parikh K, Pulido T, et al.Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension:a randomized, controlled trial[J].Circulation, 2013, 127 (5) :624-633.
                                    </a>
                                </li>
                                <li id="142">


                                    <a id="bibliography_17" title="Zamanian RT, Levine DJ, Bourge RC, et al.An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension[J].Pulm Circ, 2016, 6 (3) :329-337." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension">
                                        <b>[17]</b>
                                        Zamanian RT, Levine DJ, Bourge RC, et al.An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension[J].Pulm Circ, 2016, 6 (3) :329-337.
                                    </a>
                                </li>
                                <li id="144">


                                    <a id="bibliography_18" title="Gali&#232;N, Humbert M, Vachi&#233;ry JL, et al.Effects of beraprost sodium, an oral prost-acyclin analogue, in patients with pulmonary arterial Hypertens:a randomized, double-blind placebo-controlled trial[J].J Am Coll Cardiol, 2002, 39 (9) :1496-1502." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100362774&amp;v=Mjk1MzRzOW9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVXJmSUlGd1RhUlk9TmlmT2ZiSzdIdERPcm85RlorME5DMw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[18]</b>
                                        Gali&#232;N, Humbert M, Vachi&#233;ry JL, et al.Effects of beraprost sodium, an oral prost-acyclin analogue, in patients with pulmonary arterial Hypertens:a randomized, double-blind placebo-controlled trial[J].J Am Coll Cardiol, 2002, 39 (9) :1496-1502.
                                    </a>
                                </li>
                                <li id="146">


                                    <a id="bibliography_19" title="Sitbon O, Channick R, Chin KM, et al.Selexipag for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2015, 373 (26) :2522-2533." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Selexipag for the treatment of pulmonary arterial hypertension">
                                        <b>[19]</b>
                                        Sitbon O, Channick R, Chin KM, et al.Selexipag for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2015, 373 (26) :2522-2533.
                                    </a>
                                </li>
                                <li id="148">


                                    <a id="bibliography_20" title="McLaughlin VV, Channick R, Chin K, et al.Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension:results of the GRIPHON study[J].J Am Coll Cardiol, 2015, 65 (10) :A1538." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES80F90DC9FE105CE4C2E4F0B12616567C&amp;v=MDE4NjZKZzZFcDVQbitRclJBemVMU1JRNzNzQ09OdkZTaVdXcjdKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeExxNHc2dz1OaWZPZmJ1NGFOak0yL3hNRXA0T0RIbEt1aA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[20]</b>
                                        McLaughlin VV, Channick R, Chin K, et al.Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension:results of the GRIPHON study[J].J Am Coll Cardiol, 2015, 65 (10) :A1538.
                                    </a>
                                </li>
                                <li id="150">


                                    <a id="bibliography_21" title="Vitulo P, Stanziola A, Confalonieri M, et al.Sildenafil in severe pulmonary hyper-tension associated with chronic obstructive pulmonary disease:a randomized controlled multicenter clinical trial[J].J Heart Lung Transplant, 2017, 36 (2) :166-174." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease:a randomized controlled multicenter clinical trial">
                                        <b>[21]</b>
                                        Vitulo P, Stanziola A, Confalonieri M, et al.Sildenafil in severe pulmonary hyper-tension associated with chronic obstructive pulmonary disease:a randomized controlled multicenter clinical trial[J].J Heart Lung Transplant, 2017, 36 (2) :166-174.
                                    </a>
                                </li>
                                <li id="152">


                                    <a id="bibliography_22" title="Gali&#232;N, Brundage BH, Ghofrani HA, et al.Tadalafil therapy for pulmonary arterial Hypertens[J].Circulation, 2009, 119 (22) :2894-2903." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000037258&amp;v=MDExMTVUNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRndUYVJZPU5pZmNaYks2SDlIUHI0OUZaT2dJRG5reG9CTQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[22]</b>
                                        Gali&#232;N, Brundage BH, Ghofrani HA, et al.Tadalafil therapy for pulmonary arterial Hypertens[J].Circulation, 2009, 119 (22) :2894-2903.
                                    </a>
                                </li>
                                <li id="154">


                                    <a id="bibliography_23" title="Oudiz RJ, Brundage BH, Gali&#232;N, et al.Tadalafil for the treatment of pulmonary arterial hypertension:a double-blind 52-week uncontrolled extension study[J].J Am Coll Cardiol, 2012, 60 (8) :768-774." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100331669&amp;v=MjAzMTdpbmxVcmZJSUZ3VGFSWT1OaWZPZmJLN0h0RE9ybzlGWitnT0Nub3dvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0Rg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[23]</b>
                                        Oudiz RJ, Brundage BH, Gali&#232;N, et al.Tadalafil for the treatment of pulmonary arterial hypertension:a double-blind 52-week uncontrolled extension study[J].J Am Coll Cardiol, 2012, 60 (8) :768-774.
                                    </a>
                                </li>
                                <li id="156">


                                    <a id="bibliography_24" title="Jing ZC, Yu ZX, Shen JY, et al.Vardenafil in pulmonary arterial Hypertens:a randomized, double-blind, placebo-controlled study[J].Am J Respir Crit Care Med, 2011, 183 (12) :1723-1729." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study">
                                        <b>[24]</b>
                                        Jing ZC, Yu ZX, Shen JY, et al.Vardenafil in pulmonary arterial Hypertens:a randomized, double-blind, placebo-controlled study[J].Am J Respir Crit Care Med, 2011, 183 (12) :1723-1729.
                                    </a>
                                </li>
                                <li id="158">


                                    <a id="bibliography_25" title="Ghofrani HA, Gali&#232;N, Grimminger F, et al.Riociguat for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2013, 369 (4) :330-340." target="_blank"
                                       href="http://scholar.cnki.net/result.aspx?q=Riociguat for the treatment of pulmonary arterial hypertension">
                                        <b>[25]</b>
                                        Ghofrani HA, Gali&#232;N, Grimminger F, et al.Riociguat for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2013, 369 (4) :330-340.
                                    </a>
                                </li>
                                <li id="160">


                                    <a id="bibliography_26" title="Makowski CT, Rissmiller RW, Bullington WM.Riociguat:a novel new drug for treatment of pulmonary hypertension[J].Pharmacotherapy, 2015, 35 (5) :502-519." target="_blank"
                                       href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD15052700000841&amp;v=MDg2MTRud1plWnRGaW5sVXJmSUlGd1RhUlk9TmlmY2FySzlIdFRPcUk5RlpPc1BCSGc0b0JNVDZUNFBRSC9pclJkR2VycVFUTQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">
                                        <b>[26]</b>
                                        Makowski CT, Rissmiller RW, Bullington WM.Riociguat:a novel new drug for treatment of pulmonary hypertension[J].Pharmacotherapy, 2015, 35 (5) :502-519.
                                    </a>
                                </li>
                            </ul>
                            <div style='display: none;' class="zqscroller" >
                                <h4 class="">附加材料</h4>
                                <ul></ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
            &nbsp;
            <!--此处有一空格符 勿删-->
        </div>

        
    <div class="content">



        <!--tips start-->
                            <div class="tips">
                    <a href="http://navi.cnki.net/KNavi/JournalDetail?pcode=CJFD&amp;pykm=XXGK" target="_blank">心血管康复医学杂志</a>
                2019,28(04),509-512 DOI:10.3969/j.issn.1008-0074.2019.04.30            </div>
        <!--tips end-->
            <div class="top-title">
                <h1 class="title">
                    <span class="vm"><b>慢性阻塞性肺疾病相关性肺动脉高压的治疗现状</b></span>
                                    </h1>

            </div>
                        <h2>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E9%99%B6%E4%BC%A0%E8%8A%B1&amp;code=42560811&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">陶传花</a>
                                <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=au&amp;skey=%E5%90%B4%E7%82%B3%E7%A5%A5&amp;code=22929578&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">吴炳祥</a>
                </h2>
                    <h2>
                    <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=in&amp;skey=%E5%93%88%E5%B0%94%E6%BB%A8%E5%8C%BB%E7%A7%91%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%BA%8C%E5%8C%BB%E9%99%A2%E5%BF%83%E5%86%85%E7%A7%91&amp;code=1044277&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">哈尔滨医科大学附属第二医院心内科</a>
            </h2>

        
<div class="link">
    <a id="aexport" class="icon icon-output"  onclick="" href="javascript:void(0);"><i></i>导出/参考文献</a>
    
    <span class="shareBoard" onmouseover="$('#sharedet').show();$('#this').addClass('shareBoardCUR')" onmouseout="$('#sharedet').hide();$('#this').removeClass('shareBoardCUR')">
        <a class="icon icon-share" href="#"><i></i>分享<em></em></a>
        <ul class="shareHide" id="sharedet" style="display: none;">
            <li><a title="复制链接" class="copy" onclick="" href="#"><i></i>复制链接</a></li>
            <li><a title="分享到新浪微博" class="xl" onclick="" href="javascript:common.ShareAction('xl');"><i></i>新浪微博</a></li>
            <li>
                <a title="分享到微信" class="wx" onclick="" href="#"><i></i>微信扫一扫</a>
                <div class="qrcode"><img src='' alt='' /></div>
            </li>
        </ul>

    </span>
    
    <a id="RefTrack" title="创建引文跟踪" class="icon icon-track" onclick="" href="javascript:void(0);"> <i></i>创建引文跟踪 </a>
    <a id="ashoucang" title="收藏" class="icon icon-favor" onclick="" href="javascript:void(0);"><i></i>收藏</a>
    <a class="icon icon-print" onclick="window.print();" href="javascript:void(0);"><i></i>打印</a>
    
    <!--版本切换 end-->
</div>
                            <div class="data" id="a_abstract">
                <span class="keys">摘<span style="font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;</span>要：</span>
                <p>慢性阻塞性肺疾病 (COPD) 相关性肺动脉高压 (PAH) 是PAH中最常见的类型之一。近年来, 随着我国人口老龄化的加剧, COPD相关性PAH患者总数逐年上升。充分了解COPD相关性PAH的治疗现状、合理选择治疗方案已成为临床关注的焦点。</p>
            </div>
                    <div class="data" id="a_keywords">
                <span class="keys">关键词：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E9%AB%98%E8%A1%80%E5%8E%8B%2C%20%E8%82%BA%E6%80%A7&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">高血压, 肺性;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E8%82%BA%E7%96%BE%E7%97%85%2C%20%E6%85%A2%E6%80%A7%E9%98%BB%E5%A1%9E%E6%80%A7&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">肺疾病, 慢性阻塞性;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=%E6%B2%BB%E7%96%97&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">治疗;</a>
                </p>
            </div>
        
        <!--brief start-->
        
            <div class="brief">
                    <p>
                            <b>作者简介：</b>
                                                        <span>
                                    *吴炳祥, E-mail:wubingxiang1964@163.com;
                                </span>
                    </p>
                                    <p><b>收稿日期：</b>2018-01-12</p>

            </div>
                    <h1>Current therapeutic condition of chronic obstructive pulmonary disease associated pulmonary arterial hypertension</h1>
                    <h2>
                    <span>TAO Chuan-hua</span>
                    <span>WU Bing-xiang</span>
            </h2>
                    <h2>
                    <span>Department of Cardiology, Second Affiliated Hospital of Harbin Medical University</span>
            </h2>
                            <div class="data" id="a_abstractEN">
                <span class="keys">Abstract：</span>
                <p>Chronic obstructive pulmonary disease (COPD) -associated pulmonary arterial hypertension (PAH) is one of the most frequent types of PAH. In recent years, with the aging aggravates in China, total number of patients with COPD-associated PAH gradually rise. It has become a focus of attention to fully understand current therapeutic condition of COPD-associated PAH and select reasonable therapeutic program.</p>
            </div>
                    <div class="data" id="a_keywordsEN">
                <span class="keys">Keyword：</span>
                <p>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Hypertension%2C%20pulmonary&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Hypertension, pulmonary;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Pulmonary%20disease%2C%20chronic%20obstructive&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Pulmonary disease, chronic obstructive;</a>
                        <a href="/kcms/detail/knetsearch.aspx?dbcode=CJFD&amp;sfield=kw&amp;skey=Therapy&amp;code=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" target="_blank">Therapy;</a>
                </p>
            </div>
                    <div class="brief">
                
                    <p>
                            <b>Author：</b>
                                                        <span>
                                    WU Bing-xiang, E-mail:wubingxiang1964@163.com;
                                </span>
                    </p>
                                    <p><b>Received：</b> 2018-01-12</p>
                            </div>


        <!--brief start-->
                        <div class="p1">
                    <p id="54">慢性阻塞性肺疾病 (chronic obstructive pulmonary disease, COPD) 以不完全可逆的气流受限为特征, 气流受限呈进行性发展, 与肺部对有害颗粒或气体的异常炎症反应有关<citation id="162" type="reference"><link href="110" rel="bibliography" /><sup>[<a class="sup">1</a>]</sup></citation>。随着COPD的进展, 外周气道阻塞、肺实质破坏、肺血管的异常、长期慢性缺氧导致了缺氧性肺血管收缩, 肺血管内皮功能失调和肺血管重建等最终引起肺动脉高压。肺动脉高压 (pulmonary arterial Hypertens, PAH) 是多种因素引起肺动脉阻力进行性增高、肺血管重塑、右心室肥厚, 并最终引起右心衰竭甚至死亡的一种恶性心血管疾病。PAH的诊断标准为:在海平面、静息状态下, 经右心导管测量的平均肺动脉压 (mean pulmonary arterial pressure, mPAP) ≥25mmHg、肺毛细血管楔压 (pulmonary artery wedge pressure, PAWP) ≤15mmHg且肺血管阻力 (pulmonary Vasc resistance, PVR) &gt;3 Wood<citation id="163" type="reference"><link href="112" rel="bibliography" /><sup>[<a class="sup">2</a>]</sup></citation>。COPD相关性PAH属于最新的PAH临床分类中的第3类。近年来, 随着我国人口老龄化的加剧, COPD所致的PAH患者总数逐年上升, 由于基础疾病的不可逆性, 在病程晚期导致难以控制的右心力衰竭, 使预后极为恶劣。大量临床试验发现, 若能有效制止或者降低PAH, 可显著改善患者生活质量, 延缓出现右心力衰竭时间及降低病死率。本文将就COPD相关性PAH的治疗现状做一综述。</p>
                </div>
                <h3 id="55" name="55" class="anchor-tag"><b>1</b> COPD<b>基础疾病的治疗</b></h3>
                <div class="p1">
                    <p id="56">COPD急性加重期控制感染、规则应用支气管舒张药等为基本治疗措施;必要时应用糖皮质激素、正压通气治疗能显著改善疗效和患者预后; 缓解期可行流感疫苗接种;COPD相关性PAH的主要治疗措施是治疗原发病。</p>
                </div>
                <h3 id="57" name="57" class="anchor-tag"><b>2 非药物治疗</b></h3>
                <h4 class="anchor-tag" id="58" name="58">2.1 戒烟</h4>
                <div class="p1">
                    <p id="59">吸烟是COPD相关性PAH的重要致病因素之一。吸烟可导致COPD患者血管重塑, 并可导致支气管及肺小动脉的炎症反应, 诱发或加重PAH的产生。戒烟可改善患者的症状及肺功能, 故应该将戒烟贯穿于整个治疗过程中。</p>
                </div>
                <h4 class="anchor-tag" id="60" name="60">2.2 长期氧疗 (long-term oxygen therapy, LTOT) </h4>
                <div class="p1">
                    <p id="61">LTOT为治疗COPD的基本方法。肺泡低氧是COPD患者PVR和mPAP升高的重要原因之一，LTOT可以改善肺泡低氧诱导的PAH。因此LTOT可提高低氧血症型COPD患者的生存率、改善肺血流动力学参数及延缓PAH的进展<citation id="164" type="reference"><link href="114" rel="bibliography" /><sup>[<a class="sup">3</a>]</sup></citation>。在Zieli<image id="109" type="formula" href="images/XXGK201904031_10900.jpg" display="inline" placement="inline"><alt></alt></image>ski等<citation id="165" type="reference"><link href="116" rel="bibliography" /><sup>[<a class="sup">4</a>]</sup></citation>的研究中指出氧疗14～15h/d可在治疗的前两年内使肺动脉压轻度下降，尽管COPD患者的低氧血症进行性恶化，但在以后的一段时间内肺动脉压保持相对稳定，但肺血管结构异常无法改变。英国医学研究理事会（MRC）研究显示，LTOT能够阻止COPD相关性PAH患者肺动脉压力的继续升高，甚至能够降低其肺动脉压力<citation id="166" type="reference"><link href="118" rel="bibliography" /><sup>[<a class="sup">5</a>]</sup></citation>。</p>
                </div>
                <h3 id="63" name="63" class="anchor-tag"><b>3</b> PAH<b>的药物治疗</b></h3>
                <h4 class="anchor-tag" id="64" name="64">3.1 传统药物</h4>
                <div class="p1">
                    <p id="65">包括非特异性药物治疗 (基础支持治疗、吸氧、利尿剂、洋地黄类及抗凝剂等对症治疗) 和非靶向药物治疗 (钙离子通道阻滞剂、他汀类药物) 。</p>
                </div>
                <h4 class="anchor-tag" id="66" name="66">3.1.1 钙离子通道阻滞剂 (calcium channel blockers, CCBs) :</h4>
                <div class="p1">
                    <p id="67">此类药物通过抑制L型电压调控钙通道进而减少钙离子进入血管平滑肌细胞及心肌细胞, 从而舒张外周血管及降低血压。然而, 其仅对少数急性肺血管扩张试验阳性的特发性PAH患者有效, 对急性血管扩张试验不敏感的PAH患者使用 CCBs可能无效甚至有害。已证实长效硝苯地平、地尔硫卓和氨氯地平有效。由于CCBs此类药物有心率加快、头晕、低血压和周围性水肿等副作用, 应缓慢增至最大耐受剂量。</p>
                </div>
                <h4 class="anchor-tag" id="68" name="68">3.1.2 他汀类药物:</h4>
                <div class="p1">
                    <p id="69">他汀类药物是当前最有效的降脂药物。近年来一些研究发现, 他汀类药物还具有扩张血管、抑制平滑肌细胞增殖、改善内皮功能、促进血管新生、抑制炎症反应等调脂以外的作用<citation id="167" type="reference"><link href="120" rel="bibliography" /><sup>[<a class="sup">6</a>]</sup></citation>。马航等<citation id="168" type="reference"><link href="122" rel="bibliography" /><sup>[<a class="sup">7</a>]</sup></citation>选择COPD合并PAH患者45例及COPD患者40例, 将45例COPD合并PAH患者分为阿托伐他汀治疗组 (23例) 和对照组 (22例) 。治疗组在对照组常规治疗基础上加用阿托伐他汀治疗20mg口服, 每晚1次, 治疗6个月后结果显示治疗组血清8异前列腺素 (8-iso-PG) , 白介素 (IL) -6, 肺动脉收缩压 (PASP) 较同组治疗前及对照组治疗后均有降低 (<i>P</i>&lt;0.01) , 动脉血氧分压 (PaO<sub>2</sub>) 、6min步行距离 (6MWD) 较同组治疗前及对照组治疗后均有升高 (<i>P</i>&lt;0.05) 。结论显示阿托伐他汀能降低COPD合并PAH患者肺动脉压力, 改善血氧含量和运动耐力。孙娟等<citation id="169" type="reference"><link href="124" rel="bibliography" /><sup>[<a class="sup">8</a>]</sup></citation>对COPD合并PAH患者予以辛伐他汀治疗, 结果治疗后患者肺动脉压显著下降。此外, 他汀类药物还有抗氧化、抗炎和免疫调节作用, 并可减少COPD急性加重, 延缓肺功能下降等作用。</p>
                </div>
                <h4 class="anchor-tag" id="70" name="70">3.2 针对内皮细胞功能紊乱的靶向药物</h4>
                <div class="p1">
                    <p id="71">三大经典途径的靶向药物:内皮素受体拮抗剂、前列环素类靶向药物、NO信号通路相关的靶向药物。</p>
                </div>
                <h4 class="anchor-tag" id="72" name="72">3.2.1 内皮素受体拮抗剂:</h4>
                <div class="p1">
                    <p id="73">内皮素-1 (endothelin-1, ET-1) 由血管内皮细胞产生, 具有收缩血管、促进内皮增殖, 刺激平滑肌细胞增殖的作用。内皮素受体拮抗剂包括如下几类: (1) 波生坦:波生坦 (bosentan) 是一种非选择性的内皮素受体A和B的拮抗剂, 用于治疗NYHA分级为Ⅱ、Ⅲ、Ⅳ级的PAH患者。内皮素受体拮抗剂波生坦随机临床研究 (BREATHE-1) 显示, 波生坦能显著提高PAH患者运动耐量、WHO心功能分级, 延缓疾病恶化<citation id="170" type="reference"><link href="126" rel="bibliography" /><sup>[<a class="sup">9</a>]</sup></citation>。内皮素受体拮抗剂波生坦治疗轻度肺动脉高压临床研究 (EARLY) 发现, 使用波生坦治疗6个月后, 可显著改善PAH患者的运动耐量和血流动力学指标。有研究发现, 波生坦的疗效能够长期维持, 受试患者4年生存率提高至85%, 大部分受试患者的心功能分级也有改善<citation id="171" type="reference"><link href="128" rel="bibliography" /><sup>[<a class="sup">10</a>]</sup></citation>。主要副作用为肝损伤, 减量或停药后肝功能可恢复;此药亦有致畸作用, 禁用于孕妇; (2) 安立生坦:安立生坦 (ambrisentan) 是一种选择性的内皮素受体A拮抗剂。该药已被批准用于世界卫生组织 (WHO) 功能分级为Ⅱ、Ⅲ级的PAH患者。在安立生坦治疗肺动脉高压疗效研究 (ARIES-1) 和安立生坦治疗肺动脉高压随机、双盲、安慰剂对照、多中心有效性研究2 (ARIES-2) 研究探索了不同剂量 (ARIES-1试验为5mg和10mg, ARIES-2试验为2.5mg和5mg) 安立生坦对PAH的疗效, 研究证实该药可改善PAH患者症状、运动耐量, 并延迟临床恶化时间<citation id="172" type="reference"><link href="130" rel="bibliography" /><sup>[<a class="sup">11</a>]</sup></citation>。安立生坦的不良反应包括周围水肿、头痛、恶心等; (3) 马西替坦:马西替坦 (macitentan) 是一种新型内皮素受体拮抗剂, 可双重拮抗内皮素A和B受体。在一项研究中, PAH患者被随机分为安慰剂组及马西替坦 (3或10mg, qd) 治疗组, 结果显示, 马西替坦可提高患者的运动耐量, 延缓病情恶化时间, 降低死亡率和发病率, 马西替坦 (10mg, qd) 能够显著降低患者的住院率<citation id="173" type="reference"><link href="132" rel="bibliography" /><link href="134" rel="bibliography" /><sup>[<a class="sup">12</a>,<a class="sup">13</a>]</sup></citation>。该药无肝毒性, 但可引起血红蛋白降低。</p>
                </div>
                <h4 class="anchor-tag" id="74" name="74">3.2.2 前列环素类靶向药物:</h4>
                <div class="p1">
                    <p id="75">前列环素 (PGI2) 可特异性地结合于细胞表面前列环素受体, 导致环磷酸腺苷 (cAMP) 产生增加, 从而发挥舒张血管、抑制血小板聚集、抑制血管平滑肌细胞增殖和迁移等作用<citation id="174" type="reference"><link href="136" rel="bibliography" /><sup>[<a class="sup">14</a>]</sup></citation>。其药物包括如下几类。 (1) 依前列醇:依前列醇是首个被美国食品药品监督管理局 (FDA) 批准用于治疗PAH的PGI2类似物, 半衰期短, 稳定性差, 需低温、持续管路泵入。相关研究发现, 注射用依前列醇可实现持续降低肺动脉压力, 有效提高平均生存率, 尤其是用于WHO心功能分级 (WHO-FC) Ⅲ、Ⅳ级的PAH患者, 其6MWD较治疗前显著提高<citation id="175" type="reference"><link href="138" rel="bibliography" /><sup>[<a class="sup">15</a>]</sup></citation>。依前列醇使用时主要问题有输注泵功能障碍、局部感染、导管梗阻及导管相关感染; (2) 伊洛前列素:伊洛前列素是化学性质相对稳定的PGI2类似物, 半衰期较短, 有吸入和静脉两种给药方式。其中雾化吸入给药, 于2004年被美国FDA批准用于治疗PAH, 但静脉给药治疗尚未被批准。临床主要用于WHO-FC Ⅲ和Ⅳ级的PAH患者。患者对伊洛前列素有很好的耐受性, 副作用主要为颜面潮红及下颌痛等; (3) 曲前列环素:曲前列环素为稳定的前列环素类似物, 半衰期约4h, 可通过皮下、静脉、吸入或口服等多种途径给药。推荐用于WHO-FCⅢ和Ⅳ级的PAH患者。Jing等<citation id="176" type="reference"><link href="140" rel="bibliography" /><sup>[<a class="sup">16</a>]</sup></citation>对349例未接受过内皮素受体拮抗剂 (ERA) 和5型磷酸二酯酶抑制剂 (PDE-5i) 治疗的PAH患者进行的临床研究发现, 口服曲前列环素, 可显著改善患者的运动耐量。有研究显示, 患者日常用药耐受, 并且安全范围较广, 只有少于1%的人会出现呼吸道相关的不良事件<citation id="177" type="reference"><link href="142" rel="bibliography" /><sup>[<a class="sup">17</a>]</sup></citation>。最常见不良反应为输注部位疼痛; (4) 贝前列素:贝前列素是第一个前列环素类似物口服制剂, 半衰期为 35～40min, 可口服给药。在一项研究中, NYHA心功能分级Ⅱ～Ⅲ级的PAH患者在接受贝前列素治疗后, 运动耐量和症状显著改善, 但治疗初期药物相关的不良反应较显著<citation id="178" type="reference"><link href="144" rel="bibliography" /><sup>[<a class="sup">18</a>]</sup></citation>; (5) 前列环素信号通路的新药:Selexipag是一种选择性的前列环素IP受体激动剂。一项Ⅲ期临床研究GRIPHON (Selexipag治疗第一大类PAH的随机双盲、安慰剂对照、事件驱动的Ⅲ期国际多中心临床试验) 中, 共入选1156例PAH患者, 其中47%已接受ERA或PDE-5i单药治疗、32%已接受ERA和PDE-5i联合治疗和21%未经治疗的PAH患者, 随机分为Selexipag治疗组和安慰剂对照组, 结果发现, Selexipag能降低受试患者的发病率和主要终点事件发生风险, 但两组受试患者的死亡率无显著差异<citation id="179" type="reference"><link href="146" rel="bibliography" /><link href="148" rel="bibliography" /><sup>[<a class="sup">19</a>,<a class="sup">20</a>]</sup></citation>。主要不良反应为头痛、胃肠道反应、下颌痛、四肢痛及关节痛等。</p>
                </div>
                <h4 class="anchor-tag" id="76" name="76">3.2.3 NO信号通路相关的靶向药物:</h4>
                <div class="p1">
                    <p id="77">包括PDE-5i (西地那非、他达拉非、伐地那非) 和可溶性鸟苷酸环化酶 (sGC) 激动剂 (Riociguat) 两大类。 (1) 西地那非:西地那非 (sildenafil) 是一种口服的PDE-5i, 半衰期约为4h, 主要推荐用于WHO-FCⅡ、Ⅲ和Ⅳ级的PAH患者。在COPD相关的严重PAH患者中进行的临床研究发现, 西地那非能改善患者的血流动力学、生活质量和BODE指数 (body mass index, airflow obstruction, dyspnea and exercise capacity index) , 但对PaO<sub>2</sub>无显著影响<citation id="180" type="reference"><link href="150" rel="bibliography" /><sup>[<a class="sup">21</a>]</sup></citation>。不良反应主要有头痛、颜面潮红、鼻出血等, 但多为一过性或轻中度; (2) 他达拉非:他达拉非 (tadalafil) 是一种口服的长效PDE-5i, 半衰期长, 主要推荐用于WHO-FCⅡ、Ⅲ和Ⅳ级的PAH患者。在他达拉非治疗肺动脉高压临床试验 (PHIRST) -1的临床研究中, PAH患者分别接受2.5、10、20、40 mg (qd) 他达拉非治疗, 结果显示, 该药40 mg (qd) 剂量组受试者的运动耐量和生活质量显著改善, 且临床恶化时间延缓<citation id="181" type="reference"><link href="152" rel="bibliography" /><sup>[<a class="sup">22</a>]</sup></citation>。而且, 在PHIRST-2的扩展临床研究中, 受试PAH患者在接受他达拉非 (20和40 mg, qd) 口服治疗后, 血流动力学指标都有改善<citation id="182" type="reference"><link href="154" rel="bibliography" /><sup>[<a class="sup">23</a>]</sup></citation>。其副作用与西地那非相似; (3) 伐地那非:伐地那非 (vardenafil) 是一种口服的PDE-5i, 半衰期约为4h, 主要推荐用于WHO-FCⅡ、Ⅲ和Ⅳ级的PAH患者。一项名为EVALUATION (伐地那非治疗肺动脉高压的疗效和安全性临床试验) 研究表明, 伐地那非可改善PAH患者的运动耐量、血流动力学, 也可延迟临床恶化时间<citation id="183" type="reference"><link href="156" rel="bibliography" /><sup>[<a class="sup">24</a>]</sup></citation>。伐地那非目前尚未被美国FDA批准用于治疗PAH; (4) Riociguat:利奥西呱是一种sGC激活剂, 能增加sGC对内源NO的敏感性, 具有抗增殖、舒张肺血管等作用。在一项名为PATENT-1 (第一大类肺动脉高压的可溶性鸟苷酸环化酶刺激试验) 研究中, Riociguat可显著改善患者运动耐量、肺循环血流动力学、心功能分级, 延长临床恶化时间<citation id="184" type="reference"><link href="158" rel="bibliography" /><sup>[<a class="sup">25</a>]</sup></citation>。该药已被FDA批准用于治疗PAH患者, 其与PDE-5i合用可引起系统性低血压等副作用。由于可引起低血压, 依据收缩压剂量逐步增加, PATENT-1和慢性血栓栓塞性肺动脉高压的可溶性鸟苷酸环化酶刺激试验 (CHEST) -1研究在长期的观察中发现耐受性良好<citation id="185" type="reference"><link href="160" rel="bibliography" /><sup>[<a class="sup">26</a>]</sup></citation>。</p>
                </div>
                <h4 class="anchor-tag" id="78" name="78">3.3 其他新型靶向药物</h4>
                <div class="p1">
                    <p id="79">酪氨酸激酶受体拮抗剂、Rho激酶抑制剂、5-羟色胺再摄取抑制剂等药物均在临床试验阶段。</p>
                </div>
                <h3 id="80" name="80" class="anchor-tag"><b>4 中药治疗</b></h3>
                <div class="p1">
                    <p id="81">近年来, 中药在COPD相关性PAH的治疗方面积累了许多经验。相关研究显示很多中药有降低肺动脉压的作用, 如红花、黄芪、丹参、川芎、当归具有降低血小板表面活性, 抑制血小板聚集, 提高纤维蛋白溶解酶活性, 抑制微血栓形成, 降低血黏稠度, 改善肺循环, 降低肺动脉压的作用。中药在COPD相关性PAH的治疗方面的优势逐渐显著, 值得我们进一步深入研究。</p>
                </div>
                <h3 id="82" name="82" class="anchor-tag"><b>5 手术治疗</b></h3>
                <div class="p1">
                    <p id="83">包括肺移植和心肺联合移植, 但受器官移植供体的限制。</p>
                </div>
                <h3 id="84" name="84" class="anchor-tag"><b>6 结 语</b></h3>
                <div class="p1">
                    <p id="85">综上所述, 近年来对COPD相关性PAH的治疗研究已经取得了一定的进展。COPD基础疾病的治疗对延缓PAH的发生、发展十分重要, 戒烟及长期氧疗是治疗COPD相关性PAH最根本的方法。靶向药物治疗COPD相关性PAH的新药不断被发现, 但是疗效尚在探讨中, 其临床价值和推广应用尚有待更多的临床研究工作证实。笔者相信随着COPD相关性PAH治疗的不断深入研究, 新的药物和治疗方法会不断出现。</p>
                </div>

        <!--brief end-->
        
        <!--conten left  end-->
        <!--增强附件-->
        

        <!--reference start-->
            <div class="reference anchor-tag" id="a_bibliography">
                    <h3>参考文献</h3>
                                        <p id="110">
                            <a id="bibliography_1" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Epidemiology of chronic obstructive pulmonary disease (COPD)">

                                <b>[1]</b>Viegi G, Scognamiglio A, Baldacci S, et al.Epidemiology of chronic obstructive pulmonary disease (COPD) [J].Respiration, 2001, 68 (1) :4-19.
                            </a>
                        </p>
                        <p id="112">
                            <a id="bibliography_2" target="_blank" href="http://scholar.cnki.net/result.aspx?q=2015 ESC/ERSGuidelines for the Diagnosis and Treatment of Pulmonary Hypertension:The joint task force for the diagnosis and treatment of pulmonary Hypertens of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS):Endorsed by:As">

                                <b>[2]</b>GalièN, Humbert M, Vachiery JL, et al.2015 ESC/ERSGuidelines for the Diagnosis and Treatment of Pulmonary Hypertension:The joint task force for the diagnosis and treatment of pulmonary Hypertens of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) :Endorsed by:Association for European Paediatric and Congenital cardiology (AEPC) , international Society for Heart and Lung Transplantation (ISHLT) [J].Eur Heart J, 2016, 37 (1) :67-119.
                            </a>
                        </p>
                        <p id="114">
                            <a id="bibliography_3" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxaemia">

                                <b>[3]</b>Lee JH, Oh YM, Seo JB, et al.Pulmonary artery pressure in chronic obstructive pulmonary disease without resting hypoxiema[J].Int J Tubere Lung Dis, 2011, 15 (6) :830-837.
                            </a>
                        </p>
                        <p id="116">
                            <a id="bibliography_4" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES5BE5F65D13A2B90743D2A064E598942C&amp;v=MjUzNTlKSUZwbWFCdUhZZk9HUWxmQnJMVTA1dEJoeExxNHc2dz1OaWZPZmJiS2E5UzZxWW94WmVoK0RnNHd6eEVYNlV0L09YL2txR2N3Y0xxZFFianNDT052RlNpV1dyNw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[4]</b>Zielin'ski J, Tobiasz M, Hawrylkiewicz I, et al.Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients:a 6-year prospective study[J].Chest, 1998, 113 (1) :65-70.
                            </a>
                        </p>
                        <p id="118">
                            <a id="bibliography_5" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial">

                                <b>[5]</b>Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease:a clinical trial.Nocturnal Oxygen Therapy Trial Group[J].Ann Intern Med, 1980, 93 (3) :391-398.
                            </a>
                        </p>
                        <p id="120">
                            <a id="bibliography_6" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000030749&amp;v=MTYyNDhhUlk9TmlmY1piSzZIOUhQcjQ5RlpPZ1BDM2d3b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZ3VA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[6]</b>Halcox JP, Deanfield JE.Beyond the laboratory:clinical implications for statin pleiotropy[J].Circulation, 2004, 109 (21Suppl 1) :II42-II48.
                            </a>
                        </p>
                        <p id="122">
                            <a id="bibliography_7" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SXYX201403014&amp;v=MTEyNjRSN3FmWnVabUZ5am5WTHpNTmpYU2RyRzRIOVhNckk5RVlJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1U=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[7]</b>马航, 何海艳, 邱海艳, 等.阿托伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者的临床作用及其机制[J].山西医科大学大学学报, 2014, 45 (3) :204-208.
                            </a>
                        </p>
                        <p id="124">
                            <a id="bibliography_8" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=HAIN201402004&amp;v=MzAyMzBabUZ5am5WTHpNTFN6Q1lMRzRIOVhNclk5RllJUUtESDg0dlI0VDZqNTRPM3pxcUJ0R0ZyQ1VSN3FmWnU=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[8]</b>孙娟, 丁毅鹏.辛伐他汀治疗慢性阻塞性肺疾病合并肺动脉高压疗效观察[J].海南医学, 2014, 25 (2) :164-166.
                            </a>
                        </p>
                        <p id="126">
                            <a id="bibliography_9" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Bosentan therapy for pulmonary arterial hypertension">

                                <b>[9]</b>Rubin LJ, Badesch DB, Barst RJ, et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med, 2002, 346 (12) :896-903.
                            </a>
                        </p>
                        <p id="128">
                            <a id="bibliography_10" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14032300042824&amp;v=MjcxMjhhUlk9TmlmT2ZiSzhIdExPckk5RlpPOE5CSDQ5b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZ3VA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[10]</b>Simonneau G, Galie N, Jansa P, et al.Long-term Results:from the EARLY study of bosentan in WHO functional class IIpulmonary arterial hypertension patients[J].Int J Cardiol, 2014, 172 (2) :332-339.
                            </a>
                        </p>
                        <p id="130">
                            <a id="bibliography_11" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000036164&amp;v=MjE1ODlIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRndUYVJZPU5pZmNaYks2SDlIUHI0OUZaT2dKRFhvOW9CTVQ2VDRQUQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[11]</b>GalièN, Olschewski H, Oudiz RJ, et al.Ambrisentan for the treatment of pulmonary arterial hypertension:results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (AR-IES) study 1and 2[J].Circulation, 2008, 117 (23) :3010-3019.
                            </a>
                        </p>
                        <p id="132">
                            <a id="bibliography_12" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Macitentan and morbidity and mortality in pulmonary arterial hypertension">

                                <b>[12]</b>Pulido T, Adzerikho I, Channick RN, et al.Macitentan and morbidity and mortality in pulmonary arterial hypertension[J].N Engl J Med, 2013, 369 (9) :809-818.
                            </a>
                        </p>
                        <p id="134">
                            <a id="bibliography_13" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES14110700520358&amp;v=MTk5NDFla1BEM2t4b0JNVDZUNFBRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZ3VGFSWT1OaWZPZmJLOEg5RE1xSTlGWQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[13]</b>Channick RN, Delcroix M, Ghofrani HA, et al.Effect of macitentan on hospitalizations:results:from the SERAPHINtrial[J].JACC Heart Fail, 2015, 3 (1) :1-8.
                            </a>
                        </p>
                        <p id="136">
                            <a id="bibliography_14" target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=SYIY201415006&amp;v=MjIzMjBOalRDZDdHNEg5WE5xbzlGWW9RS0RIODR2UjRUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblZMek0=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[14]</b>张晓春, 管丽华, 潘文志, 等.肺动脉高压靶向药物治疗进展[J].上海医药, 2014, 35 (15) :9-13.
                            </a>
                        </p>
                        <p id="138">
                            <a id="bibliography_15" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES9AED8CCF91CB6B02393081EA42AAEDBD&amp;v=MTQ3MzZiZXA4Zm5wTHp4UVE0eng5UUg2WDNSWTNDTVBoTWNqckNPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTFUwNXRCaHhMcTR3Nnc9TmlmT2ZickphNlhFM1B3eg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[15]</b>Tokunaga N, Ogawa A, Ito H, et al.Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial Hypertens[J].J Cardiol, 2016, 68 (6) :542-547.
                            </a>
                        </p>
                        <p id="140">
                            <a id="bibliography_16" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK13030500001084&amp;v=MTQxMDhRSC9pclJkR2VycVFUTW53WmVadEZpbmxVcmZJSUZ3VGFSWT1OaWZjWmJLN0h0TE1xbzlGWk9zT0RIUTlvQk1UNlQ0UA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[16]</b>Jing ZC, Parikh K, Pulido T, et al.Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension:a randomized, controlled trial[J].Circulation, 2013, 127 (5) :624-633.
                            </a>
                        </p>
                        <p id="142">
                            <a id="bibliography_17" target="_blank" href="http://scholar.cnki.net/result.aspx?q=An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension">

                                <b>[17]</b>Zamanian RT, Levine DJ, Bourge RC, et al.An observational study of inhaled-treprostinil respiratory-related safety in patients with pulmonary arterial hypertension[J].Pulm Circ, 2016, 6 (3) :329-337.
                            </a>
                        </p>
                        <p id="144">
                            <a id="bibliography_18" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100362774&amp;v=MTI4MzNlWnRGaW5sVXJmSUlGd1RhUlk9TmlmT2ZiSzdIdERPcm85RlorME5DM3M5b0JNVDZUNFBRSC9pclJkR2VycVFUTW53Wg==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[18]</b>GalièN, Humbert M, Vachiéry JL, et al.Effects of beraprost sodium, an oral prost-acyclin analogue, in patients with pulmonary arterial Hypertens:a randomized, double-blind placebo-controlled trial[J].J Am Coll Cardiol, 2002, 39 (9) :1496-1502.
                            </a>
                        </p>
                        <p id="146">
                            <a id="bibliography_19" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Selexipag for the treatment of pulmonary arterial hypertension">

                                <b>[19]</b>Sitbon O, Channick R, Chin KM, et al.Selexipag for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2015, 373 (26) :2522-2533.
                            </a>
                        </p>
                        <p id="148">
                            <a id="bibliography_20" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES80F90DC9FE105CE4C2E4F0B12616567C&amp;v=MDAyNjJVMDV0Qmh4THE0dzZ3PU5pZk9mYnU0YU5qTTIveE1FcDRPREhsS3VoSmc2RXA1UG4rUXJSQXplTFNSUTczc0NPTnZGU2lXV3I3SklGcG1hQnVIWWZPR1FsZkJyTA==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[20]</b>McLaughlin VV, Channick R, Chin K, et al.Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension:results of the GRIPHON study[J].J Am Coll Cardiol, 2015, 65 (10) :A1538.
                            </a>
                        </p>
                        <p id="150">
                            <a id="bibliography_21" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease:a randomized controlled multicenter clinical trial">

                                <b>[21]</b>Vitulo P, Stanziola A, Confalonieri M, et al.Sildenafil in severe pulmonary hyper-tension associated with chronic obstructive pulmonary disease:a randomized controlled multicenter clinical trial[J].J Heart Lung Transplant, 2017, 36 (2) :166-174.
                            </a>
                        </p>
                        <p id="152">
                            <a id="bibliography_22" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWK&amp;filename=SJWK12103000037258&amp;v=MTczMjlyZklJRndUYVJZPU5pZmNaYks2SDlIUHI0OUZaT2dJRG5reG9CTVQ2VDRQUUgvaXJSZEdlcnFRVE1ud1plWnRGaW5sVQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[22]</b>GalièN, Brundage BH, Ghofrani HA, et al.Tadalafil therapy for pulmonary arterial Hypertens[J].Circulation, 2009, 119 (22) :2894-2903.
                            </a>
                        </p>
                        <p id="154">
                            <a id="bibliography_23" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJES&amp;filename=SJES13012100331669&amp;v=MjQ1OTRud1plWnRGaW5sVXJmSUlGd1RhUlk9TmlmT2ZiSzdIdERPcm85RlorZ09Dbm93b0JNVDZUNFBRSC9pclJkR2VycVFUTQ==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[23]</b>Oudiz RJ, Brundage BH, GalièN, et al.Tadalafil for the treatment of pulmonary arterial hypertension:a double-blind 52-week uncontrolled extension study[J].J Am Coll Cardiol, 2012, 60 (8) :768-774.
                            </a>
                        </p>
                        <p id="156">
                            <a id="bibliography_24" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Vardenafil in Pulmonary Arterial Hypertension A Randomized, Double-blind, Placebo-controlled Study">

                                <b>[24]</b>Jing ZC, Yu ZX, Shen JY, et al.Vardenafil in pulmonary arterial Hypertens:a randomized, double-blind, placebo-controlled study[J].Am J Respir Crit Care Med, 2011, 183 (12) :1723-1729.
                            </a>
                        </p>
                        <p id="158">
                            <a id="bibliography_25" target="_blank" href="http://scholar.cnki.net/result.aspx?q=Riociguat for the treatment of pulmonary arterial hypertension">

                                <b>[25]</b>Ghofrani HA, GalièN, Grimminger F, et al.Riociguat for the treatment of pulmonary arterial hypertension[J].N Engl JMed, 2013, 369 (4) :330-340.
                            </a>
                        </p>
                        <p id="160">
                            <a id="bibliography_26" target="_blank" href="/kcms/detail/detail.aspx?dbcode=SJWD&amp;filename=SJWD15052700000841&amp;v=MTgwMzhzUEJIZzRvQk1UNlQ0UFFIL2lyUmRHZXJxUVRNbndaZVp0RmlubFVyZklJRndUYVJZPU5pZmNhcks5SHRUT3FJOUZaTw==&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">

                                <b>[26]</b>Makowski CT, Rissmiller RW, Bullington WM.Riociguat:a novel new drug for treatment of pulmonary hypertension[J].Pharmacotherapy, 2015, 35 (5) :502-519.
                            </a>
                        </p>
            </div>
        <!--reference end-->
        <!--footnote start-->
        <!--footnote end-->



    </div>

        <input id="fileid" type="hidden" value="XXGK201904031" />
        <input id="dpi" type="hidden" value="300" />
    </div>

<script>
var _hmt = _hmt || [];
(function() {
  var hm = document.createElement("script");
  hm.src = "https://hm.baidu.com/hm.js?6e967eb120601ea41b9d312166416aa6";
  var s = document.getElementsByTagName("script")[0];
  s.parentNode.insertBefore(hm, s);
})();
</script>

    


<input id="hid_uid" name="hid_uid" type="hidden" value="WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!" />
<input id="hid_kLogin_headerUrl" name="hid_kLogin_headerUrl" type="hidden" value="/KLogin/Request/GetKHeader.ashx%3Fcallback%3D%3F" />
<input id="hid_kLogin_footerUrl" name="hid_kLogin_footerUrl" type="hidden" value="/KLogin/Request/GetKFooter.ashx%3Fcallback%3D%3F" />
<div class="btn-link" style="display: none"><a target="_blank" href="/kcms/detail/detail.aspx?dbcode=CJFD&amp;filename=XXGK201904031&amp;v=MjIxMDdUNmo1NE8zenFxQnRHRnJDVVI3cWZadVptRnlqblZMek1QVFhNWmJHNEg5ak1xNDlHWllRS0RIODR2UjQ=&amp;uid=WEEvREcwSlJHSldRa1FhdXNzY2Z1OVRrR0lUaXl3ejFCL1duS1pTRmd1dz0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!">知网节</a></div>
<div class="popflow" id="popupTips" style="display: none;">
    <div class="popflowArr"></div>
    <div class="popflowCot">
        <div class="hd"><a href="javascript:void(0);" onclick="$('#popupTips').hide();$('#popupmsg').html('')" class="close">X</a></div>
        <div class="bd">
            <p class="mes" id="popupmsg" name="popupmsg"></p>
          
        </div>
    </div>
</div>
<input type="hidden" id="myexport" value="//kns.cnki.net" />

<input type="hidden" id="KPCAPIPATH" value="//ishufang.cnki.net" />
<input type="hidden" id="CitedTimes" value="" />
<div class="link" id="GLSearch" style="display: none;">
    <i class="icon-trangle"></i>
    <div class="inner">
        <a class="icon" id="copytext">复制</a>
        <a class="icon" target="_blank" onclick="searchCRFD(this)">工具书搜索</a>
    </div>
</div>




<input id="hidVirtualPath" name="hidVirtualPath" type="hidden" value="/kxreader" />
<script src="/kxreader/bundles/detail?v=842_VlRz_g1CMCLi-M0twVw-4EOFG_noWyi_OsMnrAg1"></script>

<script src="/kxreader/Scripts/layer.min.js" type="text/javascript"></script>

<div id="footerBox" class="rootw footer">
</div>
<script>
    if (typeof FlushLogin == 'function') {
        FlushLogin();
    }
    modifyEcpHeader(true);
</script>

<!--图片放大功能 start-->
<script src="/kxreader/bundles/imagebox?v=W4phPu9SNkGcuPeJclikuVE3PpRyIW_gnfjm_19nynI1"></script>

<script type="text/javascript">
    $(function () {
        var j = $.noConflict();
        j(function () {
            j(".zoom-in,.btn-zoomin").imgbox({
                'alignment': 'center',
                'allowMultiple': false,
                'overlayShow': true
            });
        })
    });
</script>
<!--图片放大功能 end-->
<div class="fixedbar">
    <div class="backtop hiddenV" id="backtop">
        <a id="backTopSide" href="javascript:scroll(0,0);" title=""></a>
    </div>
</div>
<script type="text/javascript" src="/kxreader/Scripts/MathJax-2.6-latest/MathJax.js?config=MML_HTMLorMML-full"></script>

</body>
</html>
